» Articles » PMID: 26176265

Intravenous Autologous Bone Marrow Mononuclear Cell Transplantation for Stroke: Phase1/2a Clinical Trial in a Homogeneous Group of Stroke Patients

Abstract

The goal of this clinical trial was to assess the feasibility and safety of transplanting autologous bone marrow mononuclear cells into patients suffering severe embolic stroke. Major inclusion criteria included patients with cerebral embolism, age 20-75 years, National Institute of Health Stroke Scale (NIHSS) score displaying improvement of ≤ 5 points during the first 7 days after stroke, and NIHSS score of ≥ 10 on day 7 after stroke. Bone marrow aspiration (25 or 50 mL; N = 6 patients in each case) was performed 7-10 days poststroke, and bone marrow mononuclear cells were administrated intravenously. Mean total transplanted cell numbers were 2.5 × 10(8) and 3.4 × 10(8) cells in the lower and higher dose groups, respectively. No apparent adverse effects of administering bone marrow cells were observed. Compared with the lower dose, patients receiving the higher dose of bone marrow cells displayed a trend toward improved neurologic outcomes. Compared with 1 month after treatment, patients receiving cell therapy displayed a trend toward improved cerebral blood flow and metabolic rate of oxygen consumption 6 months after treatment. In comparison with historical controls, patients receiving cell therapy had significantly better neurologic outcomes. Our results indicated that intravenous transplantation of autologous bone marrow mononuclear cells is safe and feasible. Positive results and trends favoring neurologic recovery and improvement in cerebral blood flow and metabolism by cell therapy underscore the relevance of larger scale randomized controlled trials using this approach.

Citing Articles

The Aging Immune System: A Critical Attack on Ischemic Stroke.

Xu W, Guo Y, Zhao L, Fu R, Qin X, Zhang Y Mol Neurobiol. 2024; 62(3):3322-3342.

PMID: 39271626 DOI: 10.1007/s12035-024-04464-2.


Stem cell therapy: a new hope for stroke and traumatic brain injury recovery and the challenge for rural minorities in South Carolina.

Mohamed G, Lench D, Grewal P, Rosenberg M, Voeks J Front Neurol. 2024; 15:1419867.

PMID: 39184380 PMC: 11342809. DOI: 10.3389/fneur.2024.1419867.


Activation of neurogenesis in the hippocampus is a novel therapeutic target for Alzheimer's disease.

Taguchi A, Okinaka Y, Takeda A, Okamoto T, Boltze J, Claussen C Neuroprotection. 2024; 1(2):139-142.

PMID: 38188232 PMC: 7615480. DOI: 10.1002/nep3.25.


A Randomized, Placebo-Controlled, Phase II Trial of Intravenous Allogeneic Non-HLA Matched, Unrelated Donor, Cord Blood Infusion for Ischemic Stroke.

Laskowitz D, Troy J, Poehlein E, Bennett E, Shpall E, Wingard J Stem Cells Transl Med. 2023; 13(2):125-136.

PMID: 38071749 PMC: 10872695. DOI: 10.1093/stcltm/szad080.


A review and meta-analysis of stem cell therapies in stroke patients: effectiveness and safety evaluation.

Hovhannisyan L, Khachatryan S, Khamperyan A, Matinyan S Neurol Sci. 2023; 45(1):65-74.

PMID: 37733251 PMC: 10761518. DOI: 10.1007/s10072-023-07032-z.


References
1.
Yamaguchi T . Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation : a multicenter, prospective, randomized trial. Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention.... Stroke. 2001; 31(4):817-21. DOI: 10.1161/01.str.31.4.817. View

2.
Moniche F, Gonzalez A, Gonzalez-Marcos J, Carmona M, Pinero P, Espigado I . Intra-arterial bone marrow mononuclear cells in ischemic stroke: a pilot clinical trial. Stroke. 2012; 43(8):2242-4. DOI: 10.1161/STROKEAHA.112.659409. View

3.
Takasawa M, Watanabe M, Yamamoto S, Hoshi T, Kajimoto K, Kinoshita N . "Schistotaxis" in cerebral blood flow on 99mTc-HMPAO single-photon emission computed tomography during a seizure following a stroke. Neuroradiology. 2001; 43(10):821-3. DOI: 10.1007/s002340100590. View

4.
Matsubara H, Murohara T, Ikeda U, Shintani S, Masaki H, Amano K . Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet. 2002; 360(9331):427-35. DOI: 10.1016/S0140-6736(02)09670-8. View

5.
Taguchi A, Ohtani M, Soma T, Watanabe M, Kinosita N . Therapeutic angiogenesis by autologous bone-marrow transplantation in a general hospital setting. Eur J Vasc Endovasc Surg. 2003; 25(3):276-8. DOI: 10.1053/ejvs.2002.1831. View